Furthermore, BLM-induced mouse model and TGF-β1–induced cell model were used to verify the prediction of the network pharmacology and found that WBT treatment can inhibit the levels of TGF-β and Smad3 phosphorylation and subsequently alleviate EMT and ECM accumulation in vivo and in vitro. Here, SMAD3 is linked to Bloom syndrome.